|
|
CL429 |
|
Vaxjo ID |
389 |
|
Vaccine Adjuvant Name |
CL429 |
|
Alternative Names |
CL429 is a chimeric adjuvant containing components that stimulate TLR2 and NOD2. |
|
Adjuvant VO ID |
VO_0005573
|
|
Description |
CL429 is a covalently linked chimeric adjuvant that combines the agonists Pam2C (a TLR2 agonist) and murabutide (a NOD2 agonist). It is designed to enhance immune responses when used in vaccines. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Preparation |
CL429 is prepared by chemically linking the TLR2 and NOD2 agonists, but specific preparation methods are not provided. |
|
Function |
CL429, a TLR2 and NOD2 agonist known to mimic the modulatory effect of Lactobacillus, alleviated acute leptospiral infection |
|
Safety |
CL429 has shown enhanced immunogenicity and safety in preclinical studies, but specific safety data in clinical trials are not detailed in the article. |
| References |
Tom et al., 2019: Tom JK, Albin TJ, Manna S, Moser BA, Steinhardt RC, Esser-Kahn AP. Applications of Immunomodulatory Immune Synergies to Adjuvant Discovery and Vaccine Development. Trends in biotechnology. 2019; 37(4); 373-388. [PubMed: 30470547].
|
|
